NPR takes a look at tax woes for small-scale devicemakers; Edwards gets FDA OK to start valve trial;

@FierceMedDev: Boston Sci is one step closer to getting Watchman, for irregular heartbeat, on the U.S. market. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: In his first year as CEO of Medtronic, Omar Ishrak took home a healthy $25M. Story | Follow @DamianFierce

> NPR's "Morning Edition" checked in with devicemakers as they prepare for the impending 2.3% tax, checking in with smaller devicemakers who fear the charge could put them out of business. Listen

> The FDA has granted Edwards Lifesciences ($EW) an investigational device exemption to start trials on its Intuity heart valve. News

> Speaking of the device tax, one analyst says that Baxter ($BAX) will likely suffer little from the charge, while Boston Scientific ($BSX) is the "most exposed" devicemaker. Article

> Diagnostic firm Great Basin's molecular-based tuberculosis test has demonstrated 96% accuracy in detecting a treatment-resistant form of the disease. Release

> Masimo ($MASI) has signed a distribution deal with PSS World Medical, getting the company's Pronto-7 handheld hemoglobin checker into the hands of physicians nationwide. More

Pharma News

 @FiercePharma: Glaxo will be our new No. 1 in the Top 10 Pharma Settlements special report. More | Follow @FiercePharma

> Icahn crony could profit off a seat on Forest board. Story

> GSK's Zofran arrhythmia risk leads to new label change. Item

> Bristol-Myers, AZ aim for diabetes glory with Amylin buy. News

> GSK pays $3B to wrap up host of Justice Department claims. Article

Biotech News

 @FierceBiotech: Which biotech will be the next to get swept away in the M&A wave? More | Follow @FierceBiotech

 @JohnCFierceBloomberg counts 5 $1B-plus buyouts so far this year, trending up. Also, some data I've seen suggests licensing $$ shrinking. More | Follow @JohnCFierce

 @RyanMFierce: Google's new cloud platform attracts biotech players, could rival Amazon EC2 in pharma. More | Follow @RyanMFierce

> Bristol-Myers outbids Big Pharma pack and nabs Amylin for $5.3B. Story

> Which biotech will be the next to get swept away in the M&A wave? Article

> GSK, Theravance race rivals with PhIII COPD data on LAMA/LABA combo. News

> Icahn confederate could profit off a seat on Forest board. Item

Biotech IT News

> Boehringer claims 'gamification' win in pharma. News

> Microsoft honors Bristol-Myers, Novartis and Sanofi. Article

> Pfizer boosts online offerings to German docs. Item


Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.